Key result
Ifosfamide linked to ~380% greater encephalopathy risk in sarcoma versus lymphoma patients.
Why the study?
The incidence of ifosfamide-induced encephalopathy and its associated risk factors in patients with lymphoma and sarcoma receiving ifosfamide chemotherapy were not well defined.
What are the incidence and risk factors for ifosfamide-induced encephalopathy in patients with lymphoma and sarcoma?
Population
200 patients with lymphoma and sarcoma receiving ifosfamide chemotherapy
Comparison
Sarcoma patients vs lymphoma patients; presence vs absence of risk factors
Design
Retrospective cohort study
Authors
Loading...
Sarcoma patients on ifosfamide may warrant closer encephalopathy monitoring; this cohort study leaves open prospective validation of risk factors.
Cohort (n=200)
Yes
What are the incidence and risk factors for ifosfamide-induced encephalopathy in patients with lymphoma and sarcoma?
Absolute Event Rate: 24% vs 5%
p-value: p=<0.001
Sarcoma patients and those with prior cisplatin exposure, concomitant opioids, CYP2B6 inhibitors, or specific laboratory abnormalities are at higher risk for ifosfamide-induced encephalopathy.
Szabatura et al. (2014) conducted a cohort in Lymphoma and sarcoma (n=200). Sarcoma diagnosis vs. Lymphoma diagnosis was evaluated on Ifosfamide-induced encephalopathy (p=<0.001). Patients with sarcoma receiving ifosfamide experienced a significantly higher rate of encephalopathy compared to those with lymphoma (24% vs 5%, p<0.001).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: